Vile RG - Search Results

1

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Prestwich RJ, et al. Among authors: vile rg. Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509134 Free PMC article.

2

Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.

Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Vile RG, et al. Cancer Res. 1994 Dec 1;54(23):6228-34. Cancer Res. 1994. PMID: 7954471

3

Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.

Vile RG, Hart IR. Vile RG, et al. Cancer Res. 1993 Sep 1;53(17):3860-4. Cancer Res. 1993. PMID: 8395331

4

Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter.

Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ. Vile RG, et al. Virology. 1995 Dec 1;214(1):307-13. doi: 10.1006/viro.1995.9923. Virology. 1995. PMID: 8525635 Free article.

5

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells.

Vile RG, Diaz RM, Castleden S, Chong H. Vile RG, et al. Biochem Soc Trans. 1997 May;25(2):717-22. doi: 10.1042/bst0250717. Biochem Soc Trans. 1997. PMID: 9191190 Review. No abstract available.

6

Euro targeting in Leiden: the fourth meeting of the EWGT, University of Leiden, 14-17 November 1996.

Diaz RM, Vile R. Diaz RM, et al. Gene Ther. 1997 Jun;4(6):501-3. doi: 10.1038/sj.gt.3300445. Gene Ther. 1997. PMID: 9231064 No abstract available.

7

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model.

Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG. Castleden SA, et al. Among authors: vile rg. Hum Gene Ther. 1997 Nov 20;8(17):2087-102. doi: 10.1089/hum.1997.8.17-2087. Hum Gene Ther. 1997. PMID: 9414257

8

Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Diaz RM, Eisen T, Hart IR, Vile RG. Diaz RM, et al. Among authors: vile rg. J Virol. 1998 Jan;72(1):789-95. doi: 10.1128/JVI.72.1.789-795.1998. J Virol. 1998. PMID: 9420288 Free PMC article.

9

Genetic prodrug activation therapy.

Martin LA, Vile R, Lemoine NR, Sikora K, Pandha HS. Martin LA, et al. Lancet. 1997 Dec 20-27;350(9094):1793-4. doi: 10.1016/s0140-6736(05)63633-1. Lancet. 1997. PMID: 9428248 No abstract available.

10

Gene therapy for cancer--managing expectations.

Melcher AA, Garcia-Ribas I, Vile RG. Melcher AA, et al. Among authors: vile rg. BMJ. 1997 Dec 13;315(7122):1604-7. doi: 10.1136/bmj.315.7122.1604. BMJ. 1997. PMID: 9437283 Free PMC article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

300 results

Search Page

Filters